Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Nov 14, 2014 Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
Nov 7, 2014 Celldex Presents Varlilumab Proof of Concept Data at SITC Annual Meeting 2014
What's New

2012 Form 10-K

More →Featured Events
Sep 8, 2014
1:25 PM ET
Morgan Stanley Healthcare Conference
Aug 6, 2014
4:30 PM ET
Celldex Therapeutics Second Quarter Financial Results
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 5, 2014 Form 10-Q View HTML View PDF 559.6 KB Add to Briefcase
Mar 3, 2014 Form 10-K View HTML View PDF 909.7 KB Add to Briefcase
Add to Briefcase = add file to Briefcase